From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: Optibiotix vs Skinbiotherapeutics again - short one long the other?

By Tom Winnifrith | Saturday 2 October 2021


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I have a few words on Malcolm’s article of earlier which, by definition, makes me old according to him. Pot. Kettle. I talk about the general mood of insanity. Then, in that context, I look at the Optibiotix (OPTI) vs Skinbiotherapeutics (SBTX) debate. Should one short one and go long the other as PL has suggested? I discuss what I am doing and why.

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ANP

Anpario – a recovery Buy?...

Thursday »

Cat_Fixing_Lightbulb

Bearcast issue update: all should be well

 

ORCP

Oracle Power: Cynical Foul

Time left: 12:44:31